《新股消息》荣昌生物制药(09995.HK)料治疗红斑狼疮新药快将获批上市
内地生物制药公司荣昌生物制药(09995.HK)公布在联交所主板上市计划,公司预料其研发治疗系统性红斑狼疮的核心候选药物「泰它西普」快将获批上市。公司董事长及执行董事王威东在网上记者会表示,该药推出市场的价格定位会考虑患者负担能力,及参考主要竞争对手的定价,长远而言希望该新药可早日进入国家医保名录。
对於公司是次招股与蚂蚁集团(06688.HK)撞期,首席执行官兼首席科学官房健民指是次上市是跟随公司自己的节奏,公司亦获得很多基石投资者支持,对股份成功发行有信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.